Skip to main content
    G

    Greenwich Lifesciences Inc (GLSI)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $13.76
    -1.18 (-7.90%)

    Market Cap: $219.29M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Greenwich Lifesciences Inc (GLSI) Financials: Revenue, Profit and Cash Flow

    Updated Nov 16, 2026. Financial statements from company filings, amounts in US dollars.

    Greenwich Lifesciences reported revenue of $0 for the fiscal year ended Dec 31, 2025. That year, net income was -$19.36M, operating cash flow was -$9.91M and free cash flow was -$9.91M. The quarter ended Sep 30, 2026 had revenue of $0 and net income of -$5.81M.

    Revenue and Margins

    The company reported no revenue in the fiscal year ended Dec 2025, with an operating loss of $19.45M.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$0N/AN/AN/AN/A
    Dec 2024$0N/AN/AN/AN/A
    Dec 2023$0N/AN/AN/AN/A
    Dec 2022$0N/AN/AN/AN/A
    Dec 2021$0N/AN/AN/AN/A
    Dec 2020$0N/AN/AN/AN/A
    Dec 2019$0N/AN/AN/AN/A
    Dec 2018$0N/AN/AN/AN/A
    Dec 2017N/AN/AN/AN/AN/A
    Annual, fiscal years ended Dec 2017 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Sep 2026, the net loss widened from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017
    Cost of revenue$0$0$0$0$0$0$0$3.61K$3.61K
    Gross profit$0$0$0$0$0$0$0-$3.61K-$3.61K
    Research and development$17.22M$15.48M$7.70M$6.48M$3.56M$1.06M$2.61M$1.27M$1.22M
    Operating income-$19.45M-$17.64M-$9.33M-$8.04M-$4.60M-$1.86M-$3.43M-$1.69M-$1.57M
    Net income-$19.36M-$17.41M-$8.89M-$7.83M-$4.57M-$1.86M-$3.43M-$1.69M-$1.57M
    EBITDA-$19.45M-$17.63M-$9.32M-$8.04M-$4.59M-$1.86M-$3.42M-$1.69M-$1.57M
    Fiscal years ended Dec 2017 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating income-$5.86M-$4.02M-$5.73M-$7.94M-$3.73M-$3.77M-$2.77M-$9.71M-$2.73M-$2.66M-$2.54M-$2.84M
    Net income-$5.81M-$3.95M-$5.66M-$7.92M-$3.71M-$3.75M-$2.74M-$9.67M-$2.67M-$2.61M-$2.47M-$2.75M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents of $6.18M were 100.0% of total assets of $6.18M, against total liabilities of $5.82M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017
    Total assets$6.18M$4.09M$6.99M$13.48M$27.22M$28.68M$26.67K$108.55K$27.10K
    Current assets$6.18M$4.09M$6.99M$13.47M$27.20M$28.66M$6.83K$85.10K$54
    Cash and equivalents$6.18M$4.09M$6.99M$13.47M$27.20M$28.66M$6.83K$85.10K$54
    Total liabilities$5.82M$3.19M$294.41K$262.90K$385.17K$1.05M$1.38M$10.23M$8.56M
    Short-term debtN/AN/AN/AN/AN/A$275.15K$635.15KN/AN/A
    Shareholder equity$353.22K$908.63K$6.70M$13.21M$26.83M$27.63M-$1.35M-$10.12M-$8.53M
    Fiscal years ended Dec 2017 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$5.90M$8.88M$10.51M$6.18M$3.81M$3.13M$2.75M$4.09M$5.83M$7.23M$5.51M$6.99M
    Total liabilities$7.65M$5.76M$5.24M$5.82M$1.62M$1.69M$1.44M$1.56M$842.38K$1.35M$389.61K$294.41K
    Cash and equivalents$5.90M$8.88M$10.51M$6.18M$3.81M$3.13M$2.75M$4.09M$5.82M$7.22M$5.51M$6.99M
    Shareholder equity-$1.75M$3.12M$5.27M$353.22K$2.18M$1.44M$1.31M$2.53M$4.98M$5.88M$5.12M$6.70M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017
    Operating cash flow-$9.91M-$7.27M-$6.48M-$6.20M-$4.29M-$1.15M-$293.27K-$114.95K-$120.85K
    Capital expenditures$3$3$0$3$0$0$0$0$0
    Free cash flow-$9.91M-$7.27M-$6.48M-$6.20M-$4.29M-$1.15M-$293.27K-$114.95K-$120.85K
    Share repurchasesN/AN/AN/A$7.54M$0N/AN/AN/AN/A
    Financing cash flow$12.00M$4.37M$0-$7.54M$2.84M$29.81M$215.00K$200.00K-$129.84K
    Fiscal years ended Dec 2017 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$2.98M-$1.94M-$4.70M-$3.17M-$2.67M-$2.23M-$1.83M-$1.85M-$2.58M-$1.05M-$1.78M-$2.15M
    Capital expendituresN/AN/A$3$0$7$3$4$0$0$0$5$0
    Free cash flowN/AN/A-$4.70M-$3.17M-$2.67M-$2.23M-$1.83M-$1.85M-$2.58M-$1.05M-$1.78M-$2.15M
    Last 12 quarters

    Frequently Asked Questions About GLSI

    What is Greenwich Lifesciences' annual revenue?

    Greenwich Lifesciences reported revenue of $0 for the fiscal year ended Dec 31, 2025.

    Is Greenwich Lifesciences profitable?

    No. Greenwich Lifesciences reported net income of -$19.36M for the fiscal year ended Dec 31, 2025.

    How much free cash flow does GLSI generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$9.91M minus capital expenditures of $3 produced free cash flow of -$9.91M.

    How much debt does Greenwich Lifesciences have?

    The balance sheet dated Dec 31, 2025 reported cash and equivalents of $6.18M.